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Introduction
Cigarette smoke contains > 7,000 chemicals, 
of which hundreds are known to be harmful 
and at least 69 are known to cause cancer 
[Centers for Disease Control and Prevention 
(CDC) 2010]. Although the significant 
health effects of smoking are well recognized, 
smoking remains the largest preventable 
cause of death in the United States (CDC 
2010). In addition to the deleterious direct 
effects on the person who smokes, smoking 
can also have indirect effects, for example, 
on the developing embryo or fetus. Maternal 
smoking during pregnancy is associated with 
substantial infant morbidity and mortality 
(Dietz et al. 2010). Although smoking is a 
modifiable risk behavior that influences the 
health of both the infant and the mother, only 
about 45% of women who report that they 
smoke 3 months before pregnancy quit during 
pregnancy (CDC 2012). Exposure to the fetus 
thus remains an important area of research, 
with little known about the molecular 
changes that occur in newborns in response 
to exposure in utero. Further, if these changes 
persist for an extended period of time (or are 
permanent), they could have implications for 
disease development later in life.
The “developmental origins of disease” 
hypothesis (Gluckman and Hanson 2004) 
proposes that environmental exposures occur-
ring during development can cause biological 
changes that influence disease susceptibility 
later in life. One potential mechanism is 
through an alteration of the fetal epigenome, 
which may have long-term consequences 
(Waterland and Michels 2007). One of the 
most well-studied forms of epigenetic modi-
fication is DNA methylation, which occurs 
predominantly at position C5 of cytosine 
in cytosine–guanine dinucleotides (CpGs). 
DNA methylation plays an important role in 
human health and has been associated with a 
growing number of diseases including cancer, 
imprinting disorders, and repeat-instability 
diseases (Robertson 2005).
Several studies have examined DNA 
methylation changes associated with indirect 
maternal tobacco smoke exposure in utero 
[reviewed by Suter et al. (2013)]. These 
studies have examined changes in DNA from 
placenta, cord blood, buccal cells, or granulo-
cytes by taking either a targeted (i.e., one or 
a few genes) or a more global approach (i.e., 
epigenome-wide). However, only one study to 
date has used a high-density DNA methylation 
array (the Illumina HumanMethylation450 
BeadChip), to assess DNA methylation in 
newborns related to maternal smoking during 
pregnancy (Joubert et al. 2012).
To further explore DNA methyla-
tion changes in infants related to maternal 
smoking during pregnancy, we performed an 
epigenome-wide association study (EWAS) 
using whole blood from 889 infants in the 
Norway Facial Clefts Study (NCL), including 
287 whose mothers smoked during the 
first trimester. As a replication set, we used 
publically available results [obtained from 
Supplemental, Table S1, in Joubert et al. 
(2012)] and considered two levels of repli-
cation: a) site level at the exact CpG and 
b) gene level for other CpG sites in or near 
the same gene. In addition, we considered the 
overlap between smoking-associated methyla-
tion in adults and newborns, with special 
focus on genes that may be unique to each.
Methods
Study population. The present study is based 
on infants from the NCL. NCL is a national 
population-based case–control study of cleft 
lip and cleft palate, disorders characterized by 
the incomplete fusion of the lip and/or palate 
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Background: Maternal smoking during pregnancy is associated with significant infant morbidity 
and mortality, and may influence later disease risk. One mechanism by which smoking (and other 
environmental factors) might have long-lasting effects is through epigenetic modifications such as 
DNA methylation.
oBjectives: We conducted an epigenome-wide association study (EWAS) investigating alterations 
in DNA methylation in infants exposed in utero to maternal tobacco smoke, using the Norway 
Facial Clefts Study.
Methods: The Illumina HumanMethylation450 BeadChip was used to assess DNA methylation in 
whole blood from 889 infants shortly after delivery. Of 889 mothers, 287 reported smoking—twice 
as many smokers as in any previous EWAS of maternal smoking. CpG sites related to maternal 
smoking during the first trimester were identified using robust linear regression.
results: We identified 185 CpGs with altered methylation in infants of smokers at genome-wide 
significance (q-value < 0.05; mean Δβ = ± 2%). These correspond to 110 gene regions, of which 
7 have been previously reported and 10 are newly confirmed using publicly available results. 
Among these 10, the most noteworthy are FRMD4A, ATP9A, GALNT2, and MEG3, implicated 
in processes related to nicotine dependence, smoking cessation, and placental and embryonic 
development.
conclusions: Our study identified 10 genes with newly established links to maternal smoking. 
Further, we note differences between smoking-related methylation changes in newborns and adults, 
suggesting possible distinct effects of direct versus indirect tobacco smoke exposure as well as poten-
tial differences due to age. Further work would be needed to determine whether these small changes 
in DNA methylation are biologically or clinically relevant. The methylation changes identified 
in newborns may mediate the association between in utero maternal smoking exposure and later 
health outcomes.
citation: Markunas CA, Xu Z, Harlid S, Wade PA, Lie RT, Taylor JA, Wilcox AJ. 2014. 
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during development. The study design has 
been previously described in detail (Wilcox 
et al. 2007). Briefly, between the years 1996 
and 2001, all families of newborns referred 
for cleft surgery in Norway were contacted; 
88% of those eligible agreed to participate 
(n = 573). Controls were selected by a 
random sampling of roughly 4 per 1,000 
live births in Norway during that same 
time period; 76% of those eligible agreed to 
partici pate (n = 763). NCL was approved 
by the Norwegian Data Inspectorate and 
Regional Medical Ethics Committee of 
Western Norway, and informed consent was 
provided by both the mother and father. In 
the current study, a subset of 418 facial cleft 
cases (lip only = 107, palate only = 144, lip 
and palate = 167) and 480 controls were 
selected based on DNA availability. Newborn 
blood was collected at the delivery hospital in 
plain glass capillary tubes by heel stick and 
then frozen and shipped to a central labora-
tory in Oslo for phenylketonuria and other 
routine genetic analysis. Collection was iden-
tical for cases and controls. Study population 
characteristics are shown in Tables 1 and 2.
Tobacco smoke exposure. Information 
about maternal tobacco smoke exposure 
during pregnancy was obtained through 
mother’s questionnaire around 3–4 months 
after delivery. An English translation of this 
questionnaire can be found on the study’s 
website (National Institute of Environmental 
Health Sciences 2008). Mothers were asked 
about active smoking during the first trimester 
(average number of cigarettes smoked per day 
or per month) and passive smoke exposure 
at any time during the pregnancy (average 
number of hours per day she was within 
2 m of a smoker). Environmental tobacco 
smoke exposure (passive smoking) in utero 
was not associated with DNA methylation 
in newborns [false discovery rate (FDR) 
q < 0.05], so we combined nonsmokers, 
passive (≥ 1 hr/day within 2 m of a smoker), 
and infrequent smokers (< 1 cigarette per day) 
into one group (n = 607). All active smokers 
were also combined (n = 290). We explored 
the possibility of a dose–response relation-
ship between the extent of smoke exposure 
and the level of methylation at genome-wide 
significant CpG sites (FDR q < 0.05). Three 
exposure classes were defined for this analysis: 
a) 607 non-active smokers: nonsmokers 
(n = 437), passive (n = 131), and infrequent 
smokers (n = 39), b) 141 light smokers 
(1–5 cigarettes/day), and c) 149 moderate 
(6–10 cigarettes/day; n = 107) and heavy 
(≥ 11 cigarettes/day; n = 42) smokers. For 
a CpG site to meet our criteria for a dose–
response relationship it must satisfy two 
requirements: a) a mean methylation level 
that progressively increases or decreases across 
the three categories of smoking, and b) the 
3-level smoking variable must be significant 
(FDR q < 0.05) when treated as a continuous 
variable in the robust linear regression model. 
One mother used snuff tobacco; her baby was 
excluded from all analyses.
Analys i s .  A  descr ipt ion of  DNA 
methylation data generation (Illumina 
HumanMethylation450), quality assessment, 
and pre-processing (e.g., normalization) 
are provided (see Supplemental Material, 
Methods: Data generation, Data cleaning and 
quality assessment, and Data pre-processing). 
After exclusions (See Supplemental Material, 
Methods: Data cleaning and quality assess-
ment),  889 samples (n smokers = 287, 
nnonsmokers = 602) and 357,320 CpG probes 
remained for analysis. A robust linear regres-
sion model was employed using the R 
package, MASS (Venables and Ripley 2002), 
to test the association between maternal 
smoking status (binary variable: active smokers 
versus nonsmokers and passive/ infrequent 
smokers) and methylation (β-value) at each 
CpG site, adjusting for facial cleft status 
(control, cleft lip with or without cleft palate, 
and cleft palate only), infant’s sex, and two 
technical factors: batch effects (96-well plate) 
and bisulfite conversion efficiency (model 1) 
(see Supplemental Material, Methods, Data 
pre-processing). A sensitivity analysis was 
also conducted adjusting for several potential 
confounders. Maternal alcohol consump-
tion, education, age, body mass index (BMI), 
dietary folate, folic acid supplement use, 
multivitamin use, parity, gestational age, 
and infant’s birth weight were all consid-
ered as possible confounders. Only those 
associated with maternal smoking (p < 0.05) 
Table 1. Characteristics of mothers in the study according to maternal smoking (n or mean ± SD).
Characteristic Nonsmokers Smokers p-Valuea
All mothers 602 287
Alcohol useb 4.7 × 10–4*
0 410 158
1–3 104 64
4–6 37 20
≥ 7 45 42
Education 2.7 × 10–6*
Less than high school 57 61
High school and above 545 226
Parityc 0.12
1 239 128
2 209 102
3 117 39
≥ 4 37 18
Age at delivery (years) 29.6 ± 4.9 28.0 ± 4.9 3.1 × 10–6*
Prepregnancy BMI (kg/m2) 23.6 ± 4.1 23.4 ± 4.3 0.56
Folic acid supplement (μg)d 0.02*
0 354 194
1–399 134 58
≥ 400 114 35
Dietary folate (μg) 0.18
0–171 163 88
172–214 150 56
215–264 123 65
≥ 265 136 54
Multivitaminsd 0.36
No 391 196
Yes 211 91
ap-Values were calculated from Fisher’s exact test for categorical variables and Student’s t-test for numerical variables. 
bTotal number of drinks during the first trimester. cIncludes index child. dDuring month before pregnancy and first 2 months 
of pregnancy. *Nominally associated (p < 0.05) with maternal smoking status during pregnancy (smokers vs. nonsmokers).
Table 2. Characteristics of infants in the study according to maternal smoking (n or mean ± SD).
Characteristic Nonsmokers Smokers p-Valuea
All Infants 602 287
Sex 0.25
Female 252 132
Male 350 155
Facial cleft status 1.8 × 10–4*
Control 347 126
Cleft lip with or without cleft palate 160 113
Cleft palate only 95 48
Gestational age (weeks) 38.4 ± 7.7 37.2 ± 9.9 0.06
Birth weight (kg) 3.6 ± 0.6 3.4 ± 0.7 3.4 × 10–6*
ap-Values were calculated from Fisher’s exact test for categorical variables and Student’s t-test for numerical variables. 
*Nominally associated (p < 0.05) with maternal smoking status during pregnancy (smokers vs. nonsmokers).
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(Tables 1 and 2) and that could potentially 
influence DNA methylation were added to 
the secondary model, referred to below as 
model 2. Cellular heterogeneity is a poten-
tial confounder if the distribution of blood 
cell subtypes differs by maternal smoking 
status. To correct for cellular heterogeneity, 
we implemented the method developed by 
Houseman et al. (2012) to estimate five 
different cell proportions for each sample 
and then adjust for those in our robust linear 
regression model (model 2). A reference 
data set [GSE35069 (Reinius et al. 2012)] 
was used first to identify DNA methylation 
profiles that were specific to each of the five 
cell subtypes. This information was then used 
to generate sample-specific cell proportion 
estimates that were included in model 2 to 
correct for five leukocyte subtype proportions 
(see Supplemental Material, Table S1, for a 
comparison between newborns exposed and 
unexposed). To correct for multiple testing, 
we estimated the FDR using the q-value 
framework (Storey and Tibshirani 2003).
Results
Epig enome-wide  a s s o c ia t i on  s tudy . 
Epigenome-wide association results based 
on model 1 are presented in Figure 1. In 
addition, a volcano plot and quantile–quantile 
(Q-Q) plot are provided as Supplemental 
Material (Figures S1–S2). Further adjust-
ment for potential confounders in model 2 
(maternal alcohol use, maternal education, 
maternal age at delivery, maternal folic acid 
supplement use, infant’s birth weight, and 
five different leukocyte cell type propor-
tions) did not substantively affect the results 
as assessed by examining the correlation 
between the p-values and β-coefficients across 
all CpGs tested (see Supplemental Material, 
Figure S3). The more parsimonious model, 
model 1, was therefore selected as the primary 
model. Of 357,320 CpG sites tested for asso-
ciation with maternal smoking, we identified 
185 CpG sites with altered methyla tion at 
genome-wide significance (FDR q < 0.05) 
(see Supplemental Material, Tables S2–S3) 
found within 110 gene regions. The term 
“gene region” was used to annotate CpGs 
located within or outside the transcribed 
region of a gene. The gene region for each 
CpG probe was defined as the nearest gene if 
the CpG site was intergenic or the gene itself 
if the CpG site was located within the gene 
body (see Supplemental Material, Table S3). 
Comparing exposed and unexposed infants, 
43% of the 185 CpGs had decreased methyla-
tion (negative β-coefficient), and 57% had 
increased methyla tion (positive β-coefficient). 
The average percentage change in methylation 
(mean βsmokers – mean βnonsmokers) was small, 
ranging from –8% to 7% with a mean of 
–2% for sites with decreased methyla tion and 
2% for sites showing increased methylation. 
Further annotation of the significant CpG 
sites, including distance to the closest tran-
scription start site (TSS) and whether it is 
located within a CpG island, shelf, or shore 
is provided (see Supplemental Material, 
Table S4). We compared the distribution of 
the 185 differentially methylated CpG sites 
among genomic regions (CpG island, shelf, 
shore, or non-island), using the Illumina 
HumanMethylation450 BeadChip as a refer-
ence (see Supplemental Material, Table S5). 
In particular, we observed a significant enrich-
ment for CpG shores when we examined all 
185 CpGs (chi-square test, p = 0.002); the 
same thing was observed when the analysis 
was restricted to those 80 sites with decreased 
methylation (chi-square test, p = 0.003).
The relationship between the extent of 
smoke exposure and the level of methyla-
tion was also assessed. Of the 185 genome-
wide significant CpG sites, only 107 CpGs 
(58%) showed evidence of a dose–response 
relationship (see Supplemental Material, 
Figure S4 and Table S6). When our results 
were restricted to the 23 novel CpG sites 
confirmed at the site level or gene level 
(Table 3), 18 of the sites (78%) showed a 
dose–response relationship. Expanding that 
list of 23 CpGs to include all 62 CpG sites 
confirmed at the site level or gene level, 49 
(79%) met the criteria for a dose–response 
relationship. Further, CpGs with the smallest 
p-values had the highest proportion of dose-
response relationships (see Supplemental 
Material, Table S7), with 91% of the CpGs 
showing a dose–response relationship with 
p < 1 × 10–10.
Replication using publically available 
EWAS results. We identified 185 CpGs 
(corresponding to 110 gene regions) with 
altered methylation at genome-wide signifi-
cance (FDR q < 0.05; see Supplemental 
Material, Tables S2–S3). To replicate our 
findings, we used results from the only 
previous maternal smoking study using 
Illumina HumanMethylation450 BeadChips 
[results obtained from Supplemental Table S1 
in Joubert et al. (2012); see also Supplemental 
Material, Table S8]. In the study by Joubert 
et al. (2012), which used a conservative 
Bonferroni correction for 473,844 tests 
(p < 1.06 × 10–7) as the criterion for genome-
wide significance, 26 CpGs were reported as 
genome-wide significant. We first describe 
our confirmation of those 26 CpGs (10 gene 
regions) that we further classify as either 
established (n = 5; identified previously at 
Figure 1. Manhattan plot of epigenome-wide results based on model 1. The lower gray horizontal line 
marks genome-wide significance using FDR q < 0.05 as a cutoff (n = 185 CpGs); the higher gray horizontal 
line marks genome-wide significance using a Bonferroni correction (n = 68 CpGs, p < 1.40 × 10–7). Blue 
crosses represent CpG sites that met genome-wide significance (FDR q < 0.05) and showed decreased 
methylation in infants whose mothers smoked. Red triangles represent CpG sites that met genome-wide 
significance and showed increased methylation in infants whose mothers smoked.
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genome-wide significance and replicated using 
an independent population) or implicated 
(n = 21; identified previously at genome-
wide significance, currently lacking replica-
tion). We confirmed the 5 of 26 CpG sites 
(3 gene regions: AHRR, CYP1A1, and GFI1) 
that were additionally replicated (Bonferroni 
correction for 26 tests: p < 0.0019) by Joubert 
and colleagues using an independent popula-
tion of infants born to 18 smoking and 18 
nonsmoking mothers from the Newborn 
Epigenetics Study (NEST) (Figure 2A) 
(Joubert et al. 2012). In addition, we repli-
cated 17 of the 21 CpGs that were previously 
identified at genome-wide significance, but 
not directly replicated using 36 mothers from 
NEST (p < 0.0019) although these had repli-
cation p-values ranging from 0.002 to 0.066 
(Figure 2A). Replication of those 17 sites 
established an additional 3 gene regions 
(MYO1G, CNTNAP2, LOC100507468) 
related to maternal smoking during preg-
nancy. In addition to the 22 CpGs replicated 
as described above, an additional 17 CpGs, 
located in 7 of the 10 previously implicated 
or established gene regions met genome-wide 
significance in our study, bringing the total 
number to 39 CpGs in 7 gene regions that 
were confirmed at either site level (22 CpGs 
with exact CpG site confirmation; Figure 2A) 
or gene level (17 CpGs without exact CpG 
site confirmation but in or near one of the 
10 genes). In addition to the 26 maternal 
smoking-related CpGs previously reported, 
Joubert et al. (2012) provided results for 74 
nominally significant CpGs (part of their top 
100 findings) representing 69 gene regions 
that did not meet their strict criteria for 
genome-wide significance (Bonferroni correc-
tion, p < 1.06 × 10–7). We used this set of 
results to serve as an independent replication 
set for our novel findings [146 CpGs corre-
sponding to 103 gene regions not previously 
implicated (Figure 2B; also see Supplemental 
Material, Table S8)], which we describe in 
detail below.
Using the publically available results 
consisting of 74 nominally significant CpGs, 
we find confirmation of 9 CpGs in 8 gene 
regions (GNG12, LOC284998, VGLL4, 
FRMD4A ,  CUX2 ,  MEG3 ,  FTO ,  and 
ATP9A). Further, we identified genome-wide 
significant CpGs in 2 additional gene regions 
(GALNT2 and KIF26B) where a different 
CpG site in the same gene region showed 
altered DNA methylation (i.e., the exact CpG 
sites were not identical). In total, we identified 
8 CpGs in these 2 gene regions and 15 CpGs 
in the 8 gene regions that met genome-wide 
significance in our study (FDR q < 0.05, 
Figure 2B, Table 3). This set of 10 genes is the 
focus of the discussion below. Five of these 10 
gene regions—GNG12, GALNT2, FRMD4A, 
MEG3, and FTO—contain multiple differ-
entially methylated CpG sites at genome-
wide significance. Notably, all confirmed 
sites showed the same direction of effect in 
both studies. The remaining 123 CpGs 
(representing 93 gene regions) that achieved 
genome-wide significance (FDR q < 0.05) in 
our study require further confirmation.
Smoking-related methylation changes in 
adults and newborns. We also considered our 
results in relation to three published studies 
of adult smoking that used the Illumina 
HumanMethylation450 BeadChip for their 
primary analysis (Monick et al. 2012; Shenker 
et al. 2012; Zeilinger et al. 2013). The CpG 
sites related to adult smoking include: a) 187 
genome-wide significant sites [p ≤ 1 × 10–7; 
obtained from Zeilinger et al. (2013), 
their Table S2]; b) top findings for breast 
(nsites = 17) and colon cancer (nsites = 19) 
EWASs of adult smoking [p < 1 × 10–5; 
obtained from Shenker et al. (2012), their 
Table S3], and c) top 30 differentially meth-
ylated CpGs identified in lymphoblasts and 
alveolar macrophages [some, but not all are 
genome-wide significant; obtained from 
Monick et al. (2012), their Tables 2 and 5]. 
Using these lists, we examined the overlap 
between smoking-related DNA methylation 
in adults and newborns. Of the 185 genome-
wide significant CpG sites identified in our 
study, 21 CpGs (6 gene regions) were identi-
fied with the same direction of effect in at least 
one of the three adult smoking studies (see 
Supplemental Material, Table S8).
We next sought to more generally 
compare the established smoking-related genes 
in adults and newborns (see Supplemental 
Material, Table S8). Ten gene regions were 
identified as among the top findings in at least 
two of the three adult studies. We compared 
the two newborn studies using gene regions 
from the 185 CpGs in our study and the 
100 CpGs reported by Joubert et al. (2012) 
and found 17 gene regions in common. In 
both the adult and newborn comparisons, 
the same gene region was implicated, but the 
exact CpG site may differ between studies. 
Of the 10 established gene regions identified 
in multiple adult studies, 4 were identified 
in both newborn studies (AHRR, GNG12, 
GFI1, CNTNAP2). The remaining six gene 
regions (LOC100131546, TMEM51, IER3, 
GNA12, LRP5, F2RL3) were restricted to 
adults only. In contrast, of 17 established gene 
regions identified in both newborn studies, 
6 were reported in at least one adult study 
(AHRR, CNTNAP2, GNG12, GFI1, ATP9A, 
MYO1G), whereas 11 (LOC284998, FTO, 
CUX2, CYP1A1, VGLL4, KIF26B, MEG3, 
FRMD4A, GALNT2, LOC100507468, 
EXT1) were restricted to newborns only.
Our final comparison between adult and 
newborn findings was related to the direc-
tion of methylation change. In contrast to 
newborns, where 43% of CpGs had decreased 
methylation, > 70% of the CpGs identified 
Table 3. Novel CpG sites confirmed at the site or gene level.a
Probe Chromosome Basepair (hg19) Nearest gene
Model 1 Replication:  
450Kc p-valueCoefficientb p-Value
cg25189904 1 68299493 GNG12 –0.02 9.06 × 10–9* 4.96 × 10–6
cg26764244d 1 68299511 GNG12 –0.023 6.68 × 10–10* 4.47 × 10–6
cg18703066d 2 105363536 LOC284998 –0.006 7.63 × 10–12* 3.42 × 10–7
cg18096987 3 11623873 VGLL4 –0.018 4.10 × 10–8* 2.20 × 10–6
cg20344448d 10 14372431 FRMD4A 0.015 2.97 × 10–9*
cg11813497d 10 14372879 FRMD4A 0.024 6.85 × 10–9* 3.48 × 10–6
cg25464840d 10 14372910 FRMD4A 0.022 3.15 × 10–15*
cg15507334d 10 14372913 FRMD4A 0.02 2.43 × 10–13*
cg00029284d 12 111731203 CUX2 –0.009 9.62 × 10–6 1.53 × 10–6
cg08698721d 14 101294147 MEG3 0.013 1.66 × 10–5 2.92 × 10–6
cg04291079d 14 101294430 MEG3 0.013 1.67 × 10–7
cg00253658d 16 54210496 FTO 0.059 1.37 × 10–17* 9.64 × 10–7
cg26681628 16 54210550 FTO 0.023 4.05 × 10–13*
cg03687532 16 54228358 FTO 0.012 2.41 × 10–5
cg07339236d 20 50312490 ATP9A –0.013 2.21 × 10–18* 1.38 × 10–7
cg16517298 1 230413174 GALNT2 –0.027 6.09 × 10–6
cg19727396d 1 230415185 GALNT2 –0.018 1.15 × 10–5
cg24591105d 1 230415225 GALNT2 –0.024 1.26 × 10–7*
cg00589617d 1 230415343 GALNT2 –0.029 1.07 × 10–7*
cg05697274d 1 230415377 GALNT2 –0.026 1.75 × 10–8*
cg24250902d 1 230415547 GALNT2 –0.032 1.13 × 10–8*
cg03144619d 1 230415668 GALNT2 –0.037 2.17 × 10–9*
cg09368188d 1 245330018 KIF26B 0.026 1.54 × 10–7
aSite/gene region was not part of the 26 sites/10 gene regions that met genome-wide significance in Joubert et al. 
2012 (Bonferroni correction, p < 1.06 × 10–7) but was confirmed using their results containing 74 additional nominally 
significant sites/69 gene regions. bA negative coefficient indicates reduced methylation in infants whose mothers 
smoked. cReplication at the site level using a previously published study (Joubert et al. 2012) that used Illumina 
HumanMethylation450 BeadChips. Those sites without direct confirmation were included if they were genome-wide 
significant in our study and a different CpG site in the same gene region was identified by Joubert et al. (2012) 
(e.g., GALNT2). dMet our criteria for dose response (see “Methods,” “Tobacco smoke exposure,” for details). *Met 
Bonferroni correction (p < 1.4 × 10–7). 
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in adult smokers had decreased methylation. 
However, there is some limited evidence, at 
least in adults, that this finding may be tissue 
specific (Monick et al. 2012).
Discussion
We conducted an EWAS investigating altera-
tions in DNA methylation in infants indi-
rectly exposed in utero to maternal tobacco 
smoke. We identified 185 CpG sites that met 
genome-wide significance (FDR q < 0.05). 
Publicly available results from a recent EWAS 
of maternal smoking were used to confirm 
some of our findings (Joubert et al. 2012). 
We also described similarities and differences 
between smoking-related methylation changes 
in adults and newborns.
Our study confirmed 5 of 5 previously 
replicated maternal smoking-related CpG sites 
representing 3 gene regions. We also repli-
cated another 17 of 21 CpGs, representing 
3 additional gene regions, that had achieved 
genome-wide significance in the previous 
study but were not replicated in their small 
replication population using a Bonferroni 
correction for multiple tests (Joubert et al. 
2012). Most of these CpGs, however, had 
p-values < 0.05. Most important, we provide 
new findings of 8 gene regions associated with 
maternal smoking where, using the publicly 
available results from Joubert et al. (2012), 
there was exact CpG site confirmation and 2 
gene regions where different CpGs showed 
evidence of association (Table 3). From 
this set of 10 genes with newly established 
links to maternal smoking, the most note-
worthy include MEG3 (maternally expressed 
3), FRMD4A (FERM domain containing 
4A), ATP9A (ATPase, class II, type 9A), 
and GALNT2 (UDP-N-acetyl-alpha-d-
galactosamine:polypeptide N-acetylgalactosa
minyltransferase 2), discussed in detail below.
In MEG3  we find 2 genome-wide 
significant CpGs and 1 nominally associated 
CpG with increased methylation in infants 
of mothers who smoked (see Supplemental 
Material, Figure S5). MEG3 is an imprinted 
gene (paternal allele silenced, maternal allele 
expressed) that encodes a long noncoding 
RNA implicated in tumorigenesis (Benetatos 
et al. 2011) and embryonic development 
(Zhou et al. 2010). Previous studies suggest a 
potential link between MEG3, tobacco smoke, 
and development. Expression of MEG3 is 
down-regulated in immortalized human bron-
chial epithelial cells in response to treatment 
with cigarette smoke condensate but can be 
reactivated following 5-aza-2-deoxycytidine 
treatment (Hu et al. 2009). This suggests 
that the smoking-related decrease in expres-
sion may be associated with increased DNA 
methylation, consistent with the direction 
of effect found in newborns of mothers who 
smoke. Related to development, maternal 
cigarette smoking during pregnancy causes 
reduced birth weight (Suter et al. 2013), and 
expression of MEG3 is down-regulated in 
placentae with intrauterine growth restriction 
(McMinn et al. 2006), as was observed in 
human bronchial epithelial cells treated with 
cigarette smoke condensate. However, unlike 
the direction of effect observed in the previous 
study, MEG3 is up-regulated in placentas of 
women smokers compared with nonsmokers 
(Votavova et al. 2011). Given these inconsis-
tent findings, additional studies are needed to 
clarify this relationship.
The DLK1/MEG3 imprinting domain 
on 14q32.2 has two differentially methyl-
ated regions (DMRs), the MEG3-DMR 
(secondary, postfertilization-derived DMR; 
located near our smoking-associated CpGs) 
and IG-DMR (primary, germline-derived 
intergenic DMR) (Skaar et al. 2012) that 
are hypothesized to act as imprinting control 
centers in the body and placenta, respectively 
(Kagami et al. 2010). Although the mecha-
nism by which the MEG3-DMR regulates 
imprinting is not well understood, CTCF 
(CCCTC-binding factor) is thought to be 
involved (Skaar et al. 2012), perhaps by 
modulating chromatin boundary formation 
(Wylie et al. 2000). The MEG3 smoking-asso-
ciated CpGs identified in our study are located 
at the border of the MEG3-DMR immedi-
ately adjacent to two putative CTCF binding 
sites (Wylie et al. 2000; also see Supplemental 
Material, Figure S5). If increased methyla-
tion in newborns of smokers inhibits CTCF 
binding, it could result in decreased expres-
sion of MEG3 and other maternally expressed 
genes, as well as increased expression of pater-
nally expressed genes in that region (Kagami 
et al. 2010). Dysregulation of MEG3 could 
potentially affect embryonic development and, 
if the altered methylation state persists for 
an extended period of time, have long-term 
health effects.
We identified altered methylation of 
CpGs near two genes, FRMD4A and ATP9A, 
associated with nicotine (Yoon et al. 2012) 
and substance dependence (Johnson et al. 
Figure 2. Replication of previously identified maternal smoking-related CpG sites (A) and confirmation of 
novel findings (B). GWS, genome-wide significant. (A) Twenty-six GWS CpG sites (Bonferroni correction: 
p < 1.06 × 10–7) related to maternal smoking during pregnancy were previously identified. Using our 185 
GWS CpG sites (FDR q < 0.05) related to maternal smoking during pregnancy, we further confirmed all 5 
CpGs that had been previously replicated using a separate study population (Bonferroni correction for 
26 tests; p < 0.0019) as described by Joubert et al. (2012). Further, we replicated 17 of the 21 CpGs that 
were not directly replicated in their small replication population using a Bonferroni correction for 26 tests. 
In total, 22 CpGs (6 unique gene regions) of the 26 CpGs (10 unique gene regions) were either further 
confirmed or replicated at the site level. An additional 17 CpGs, located in 7 of the 10 previously implicated 
or established gene regions, met genome-wide significance in our study, bringing the total to 39 CpGs in 
7 gene regions: 22 CpGs replicated at the site level and 17 CpGs replicated at the gene level. (B) Novel 
findings included those CpG sites in gene regions not previously identified as shown in (A). Publicly avail-
able results (Joubert et al. 2012) were used to confirm our findings. We considered two scenarios: The 
exact CpG was confirmed versus the exact CpG was not confirmed, but other CpGs were identified in the 
same gene region. 
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2008), and the ability to quit smoking (Uhl 
et al. 2008). Increased methylation at 4 CpGs 
in newborns of smokers was observed in 
FRMD4A, a scaffolding protein implicated in 
the regulation of epithelial polarity (Ikenouchi 
and Umeda 2010). Decreased methylation 
with smoking exposure was found at 1 CpG 
in ATP9A, a class 2 P4-ATPase that localizes 
to endosomes and the trans-Golgi network 
(Takatsu et al. 2011). Although findings are 
not consistent across all studies, maternal 
smoking during pregnancy has been previ-
ously associated with smoking-related traits 
in offspring (e.g., nicotine dependence) 
even after accounting for postnatal exposure 
to tobacco smoke (Al Mamun et al. 2006; 
Kandel et al. 1994; Kardia et al. 2003; Lieb 
et al. 2003; Selya et al. 2012); however, the 
possibility cannot be ruled out that these 
associations are attributable to unmeasured 
confounding. An animal study provides 
further support for an association by showing 
a neurotoxicant effect of prenatal nicotine 
exposure in rats that persisted into adoles-
cence (Abreu-Villaca et al. 2004). Authors 
suggested that if similar, persistent alterations 
occurred in offspring of mothers who smoked 
during pregnancy, this could contribute to an 
increased susceptibility of nicotine dependence 
in adolescence. Thus, if the altered meth-
ylation states of FRMD4A and/or ATP9A 
persisted through adolescence, these could 
potentially contribute to the observed relation-
ship between maternal smoking and smoking-
related traits, such as nicotine dependence, 
in offspring.
In GALNT2 we identified 7 CpGs 
at genome-wide significance that showed 
decreased methylation in newborns of 
smokers. GALNT2 is associated with lipid 
levels (Teslovich et al. 2010), insulin signaling 
(Marucci et al. 2013a), hyperglycemia 
(Marucci et al. 2013b), and the malignant 
behavior of hepatocellular carcinoma (Wu 
et al. 2011). GALNT2 may also play a role 
in extravillus trophoblast invasion, which is 
important for placental development (Liao 
et al. 2012). Aberrant DNA methylation of 
GALNT2, which has so far been identified 
only in newborns exposed and not adults, 
may affect the development of the placenta 
and could subsequently influence the health 
of the fetus.
In this study we described some unique 
and common aspects of smoking-related 
methylation changes in adults and newborns. 
Less than half of the maternal smoking–
related genes that are now well established 
in newborn studies were identified in any of 
the three published adult smoking studies. 
Moreover, some of the best-established adult 
smoking–related gene regions (e.g., F2RL3) 
were not among the top results from either 
of the newborn studies. These observations 
suggest that there could be distinct effects of 
direct tobacco smoke exposure in adults versus 
indirect tobacco smoke exposure in utero. 
There are several plausible explanations for 
this observation: 
• Age-related susceptibility: The epigenome of 
the developing embryo and fetus is thought 
to be particularly susceptible to environ-
mental exposures because many epigenetic 
changes are occurring along with rapid cell 
division (Perera and Herbstman 2011). 
• Tissue-specific alterations related to age at 
exposure: Exposure during development 
may be more likely to induce widespread 
changes (i.e., many tissues affected), whereas 
exposure during adulthood may be more 
likely to induce restricted changes, perhaps 
identifiable in only one or a few tissues 
(Rakyan et al. 2011). 
• Exposure variability: The exposure itself 
could vary with respect to duration. In 
addition, the fetus is indirectly exposed 
to tobacco smoke, so the actual exposure 
is dependent on a number of factors, 
including the ability of the placenta and 
the mother to metabolize and detoxify 
 components of the cigarette smoke. 
• Age-related differences in the response to 
exposure: Response to an environmental 
exposure, such as tobacco smoke, may vary 
by age due to differences in one’s metabolism 
and capacity to detoxify the components of 
tobacco smoke (Aldridge et al. 2003). For 
example, in response to tobacco smoke, age-
dependent expression (Eke et al. 1997) of 
genes involved in metabolizing components 
of tobacco smoke has been reported. 
• Power of the studies: It is also possible that 
future newborn and adult studies with 
larger sample sizes will find more overlap of 
these genes.
There are several limitations to our 
study. We were able to confirm only some 
of our findings using publicly available 
results. Our confirmations were based on 
the top 100 sites described in a previously 
published study (Joubert et al. 2012), so we 
are unable to comment on the total number 
of CpGs that are currently lacking replica-
tion, given the fact that we did not have 
access to a complete replication set. Even 
with this limited list we were able to identify 
10 new genes related to maternal smoking, 
including some with biologically plausible 
functions. Our correction for multiple 
testing was based on a reduced number of 
probes after filtering out the least variable 
20% of CpGs. The alternative of filtering by 
degree of difference may induce FDR bias, 
but there is no evidence of such bias when 
filtering by variability (van Iterson et al. 
2010). As a further check, we compared 
our results with and without filtering; the 
findings were essentially unchanged. Of the 
23 novel CpG sites confirmed at the site or 
gene level (Table 3), all but one remained 
significant at a genome-wide level without 
filtering (FDR q < 0.05), whereas the one 
exception (cg03687532) had an FDR 
q = 0.06. These additional results provide 
some reassurance about the robustness of 
our conclusions. Another potential limita-
tion is that we used self-reported smoking as 
opposed to a more objective measure, such 
as cotinine. However, self-reported smoking 
is generally considered to be a valid measure 
of smoking. Self-reported maternal smoking 
and plasma cotinine concentrations were 
compared in the Mother and Child Cohort 
Study, another population-based Norwegian 
study conducted during 2002–2003. That 
study reported a high level of validity for the 
self-reported data (Kvalvik et al. 2012). In our 
study, mean birth weight was reduced with 
maternal smoking (Table 2), consistent with 
the usual expected effect of smoking on the 
fetus. If there was underreporting of smoking 
during pregnancy, this type of misclassifica-
tion would only reduce our power, and would 
not explain our detection of 185 CpG sites at 
genome-wide significance. Furthermore, in 
the absence of further validation (e.g., pyro-
sequencing) and functional work, it is not 
known whether these changes are biologically 
relevant or which gene or genes they affect, if 
any. It also remains to be seen whether these 
small changes in DNA methylation will be of 
clinical relevance.
Conclusions
Consistent with previous reports, we found 
maternal smoking during pregnancy to be 
associated with an altered DNA methylation 
profile in infants. Of particular interest were 
findings in FRMD4A, ATP9A, GALNT2, 
and MEG3—genes that are implicated in 
processes related to nicotine dependence, 
smoking cessation, and placental and embry-
onic development. Further, we described some 
unique aspects of DNA methylation changes 
in adults compared with newborns. Direct 
and indirect in utero smoke exposure appear 
to elicit differential epigenetic responses that 
may be attributable to age-related differ-
ences in susceptibility to tobacco smoke, 
tissue-specific alterations related to age at 
exposure, variation in the exposure itself, and/
or age-related differences in the response to 
exposure. It remains to be seen whether the 
small changes in DNA methylation identi-
fied (mean Δβ = ± 2%) are biologically or 
clinically relevant. Future studies examining 
the persistence of DNA methylation changes 
due to an in utero exposure throughout life, 
and particularly associations of these changes 
with health phenotypes later in life (i.e., DNA 
methylation as a mediator of health effects), 
will be of particular interest.
Smoking-related methylation changes in newborns
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